Clinically and statistically significant superiority of AP301 maintenance dose versus ineffective low dose in reducing serum ...

Unlike the general population, patients on maintenance hemodialysis have both traditional and nontraditional risk factors that put them at high cardiovascular risk, despite use of standard lipid and ...

Type 1 diabetes with CKD is understudied with no advancement of therapy options since the 1990s. The FINE-ONE phase 3 trial addresses a high, unmet need for treatments.

Alexis Conell didn't think anything was wrong or experience symptoms until she learned she'd lost kidney function. Now a ...

REVB READ THE FULL REVB RESEARCH REPORT Revelation Biosciences (NASDAQ:REVB) released 3Q2025 earnings results and showed an increased cash balance of $12.7 million, due in part to a recent warrant ...

October 2025 saw a wave of M&As and biotech deals in various therapeutic fields, particularly for therapies addressing ...

Men and postmenopausal women with chronic kidney disease may have a greater risk for cognitive impairment, according to data ...

Shares of Akebia Therapeutics were trading at $2.01 as of November 06. Over the last 52-week period, shares are up 1.26%.

Early diagnosis of chronic kidney disease (CKD) gives us the best opportunity to slow the progressive nature of the disease ...

Chronic kidney disease develops silently. Kidneys filter waste, but when they weaken, toxins build up. This impacts the heart ...

For patients like Pham, Vantive’s home dialysis technologies represent more than medical equipment — they’re a pathway to a ...

In FSGS, podocytes are damaged, like a net with torn holes, allowing protein to leak into the urine, creating a harmful ...